Free Trial
NASDAQ:OCS

Oculis Q4 2024 Earnings Results & Report

Oculis logo
$7.61 -0.03 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$7.63 +0.02 (+0.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis missed analyst earnings expectations in its Q4 2024 results, released March 11, 2025. The company reported EPS of -$0.76 versus the -$0.48 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Oculis EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.28
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Oculis Revenue Results

Actual Revenue
N/A
Expected Revenue
$209 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oculis Q4 2024 Earnings FAQ

Oculis (NASDAQ:OCS) reported earnings of -$0.76 per share for Q4 2024, missing the consensus estimate of -$0.48. The report was announced on Tuesday, March 11, 2025.

Oculis Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Oculis Gains FDA IND Clearance for Privosegtor in Acute MS Relapses
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations.

Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development.

Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.

View Oculis Profile